1-4 of 4
Suzanne Kyle
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract C75: Rucaparib (CO-338) accumulation and persistence of PARP inhibition in vitro and in vivo and efficacy of intermittent vs continuous schedules.

Free
James C. Murray, Huw D. Thomas, Philip Berry, Suzanne Kyle, Christopher Jones, Ruth Plummer, Alan V. Boddy, Nicola J. Curtin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C75.
https://doi.org/10.1158/1535-7163.TARG-13-C75
Published: 01 November 2013
View article titled, Abstract C75: Rucaparib (CO-338) accumulation and persistence of PARP inhibition in vitro and in vivo and efficacy of intermittent vs continuous schedules.
Journal Articles

Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer

Free
Michael A. Batey, Yan Zhao, Suzanne Kyle, Caroline Richardson, Andrew Slade, Niall M.B. Martin, Alan Lau, David R. Newell, Nicola J. Curtin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (6): 959–967.
https://doi.org/10.1158/1535-7163.MCT-12-0707
Published: 09 June 2013
View article titled, Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer
Open the PDF for Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer in another window
Journal Articles

The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice

Free
Majid Ali, Marzieh Kamjoo, Huw D. Thomas, Suzanne Kyle, Ivanda Pavlovska, Muhammed Babur, Brian A. Telfer, Nicola J. Curtin, Kaye J. Williams
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (12): 2320–2329.
https://doi.org/10.1158/1535-7163.MCT-11-0356
Published: 07 December 2011
View article titled, The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice
Open the PDF for The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice in another window
Includes: Supplementary data
Journal Articles

Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial

Free
Huw D. Thomas, Christopher R. Calabrese, Michael A. Batey, Stacie Canan, Zdenek Hostomsky, Suzanne Kyle, Karen A. Maegley, David R. Newell, Donald Skalitzky, Lan-Zhen Wang, Stephen E. Webber, Nicola J. Curtin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (3): 945–956.
https://doi.org/10.1158/1535-7163.MCT-06-0552
Published: 15 March 2007
View article titled, Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial
Open the PDF for Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial in another window
Includes: Supplementary data